Tascenso ODT

Tascenso ODT, an approved alternative to Gilenya (fingolimod), is now available to multiple sclerosis (MS) patients in the U.S., where it’s being marketed by Cycle Pharmaceuticals. The launch comes about a month after the U.S. Food and Drug Administration approved a 0.5 mg dose of the…

Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Gilenya alternative The disease-modifying therapy (DMT) Gilenya (fingolimod) has been around since 2010. Now the U.S. Food and Drug Administration has…

The U.S. Food and Drug Administration has approved Tascenso ODT, a bioequivalent formulation of the multiple sclerosis (MS) therapy Gilenya (fingolimod), at a higher patient dose, according to the pharmaceutical company that will market the treatment in the U.S. The newly approved therapy, which is delivered as…